VHL anticorps (C-Term)

N° du produit ABIN5538403

Détail du produit anti-VHL anticorps

Antigène: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Épitope: AA 181-210, C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VHL est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Immunogène: This VHL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human VHL.

Isotype: Ig Fraction

Information d'application

Indications d'application: For WB starting dilution is: 1:1000

For IHC-P starting dilution is: 1:50~100

For FACS starting dilution is: 1:10~50

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 2 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur VHL

Antigène: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Autre désignation: VHL (VHL Produits)

Synonymes: anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992

Sujet: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Poids moléculaire: 24 kDa

ID gène: 7428

UniProt: P40337

Pathways: Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway